Slingshot Bio, Inc., a California-based company involved in precision cell mimic controls for flow cytometry, announced on Monday the commercial launch of ViaComp Ultra Amine, a next-generation compensation control designed for amine-reactive viability dyes and fluorophore-conjugated antibody panels in spectral and conventional multiparameter flow cytometry workflows.
ViaComp Ultra Amine compensation controls are precision-engineered cell mimics designed to support spectral unmixing and compensation across complex, multiparameter flow cytometry workflows. The control simultaneously captures amine-reactive viability dyes and fluorophore-conjugated antibodies from multiple host species -- including mouse, rat, hamster, rabbit, and human -- in a single, unified reagent.
Each vial contains a pre-mixed suspension of positive and negative control particles that generate clear, well-separated peaks with the fluorescence spectrum of the dye or fluorophore being tested. The ready-to-use dropper format helps eliminate the variability, fragility, and time-consuming preparation requirements associated with traditional cell-based compensation controls.
According to Slingshot, low cytometry controls are critical at every stage of assay development -- from instrument setup and panel optimisation through to established assays and inter-site harmonisation. Yet traditional biological controls such as cell lines, donor-derived PBMCs, and polystyrene beads present ongoing challenges including lot-to-lot variability, resource-intensive maintenance, limited availability for rare biomarkers, and regulatory burden.
Slingshot Bio's cell mimic platform is claimed to address these challenges by combining the biological relevance of cell-based controls with the precision, reproducibility, and scalability of semiconductor manufacturing.
ViaComp® Ultra Amine is now available through Slingshot Bio's commercial catalogue as part of the ViaComp Ultra product line, alongside ViaComp Ultra DNA. The product is manufactured under ISO 9001 quality management standards and is intended for research use only.
OmniAb signs global ion channel collaboration with Eli Lilly
HUTCHMED reports positive Phase III results for ORPATHYS and TAGRISSO combination
ArkBio's Ziresovir gains US FDA Phase II clinical trial approval
Pilot Project between BioCytics and LIDE Biotech
Pharming launches Joenja in Japan for APDS patients aged four and above
PTC to acquire BLA-stage ST-920 Fabry disease programme
ArkBio's IND application for AFC candidate AK0406 approved in China for influenza prophylaxis
Definium Therapeutics reports positive Phase 3 results for DT120 in generalised anxiety disorder